Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA2 | P16389 | 1/20 | 0.57 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 2/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | KCNA3 | P22001 | 6/20 | 0.40 |
| ▸ | KCNA5 | P22460 | 4/20 | 0.40 |
| ▸ | XDH | P47989 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7893642 | 0.86 | KCNA2 (0.58) | KCNA2CYP1A1KDM4ECYP1A2CYP1B1 | |
| SCHEMBL20278630 | 0.82 | KCNA2 (0.56) | KCNA2CYP1A1KDM4ECYP1A2CYP1B1 | |
| SCHEMBL31117604 | 0.82 | KCNA2 (0.57) | KCNA2CYP1A1KDM4ECYP1A2CYP1B1 | |
| Hydrochloric Acid SCHEMBL9222829 | 0.77 | KCNA2 (0.54) | KCNA2CYP1A1KDM4ECYP1A2CYP1B1 | |
| SCHEMBL4187228 | 0.76 | CYP3A4 (0.80) | KCNA2CYP1A1KDM4ECYP1A2CYP1B1 | |
| SCHEMBL23356474 | 0.74 | MAOA (0.65) | KCNA2KDM4ECYP1A2CYP1B1CYP3A4 | |
| SCHEMBL3014054 | 0.73 | KCNA2 (1.00) | KCNA2CYP1A1KDM4ECYP1A2CYP1B1 | |
| SCHEMBL3519659 | 0.73 | KCNA2 (0.47) | KCNA2CYP1A1KDM4ECYP1A2CYP1B1 | |
| Bromide SCHEMBL4319744 | 0.72 | KCNA2 (0.46) | KCNA2CYP1A1KDM4ECYP1A2CYP1B1 | |
| Bromide SCHEMBL8484847 | 0.71 | KCNA2 (0.44) | KCNA2CYP1A1KDM4ECYP1A2CYP1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1998022468-A1 | PSORALEN SENSITIZERS FOR VIRAL INACTIVATION | OHIO STATE RESEARCH FOUNDATION (US) | 1998-05-28 | — | — | WO | claimed |
| EP-0840781-B1 | METHODS AND DEVICES FOR THE REMOVAL OF PSORALENS FROM BLOOD PRODUCTS | CERUS CORP (US) | 2009-12-09 | — | — | EP | disclosed |
| US-6544727-B1 | Deactivating nucleic acid pathogens | CERUS CORPORATION | 2003-04-08 | — | — | US | disclosed |
| US-20020192632-A1 | Method and devices for the removal of psoralens from blood products | HEI DEREK J (US) | 2002-12-19 | — | — | US | disclosed |
| US-20020115585-A1 | Method and devices for the removal of psoralens from blood products | HEI DEREK J (US) | 2002-08-22 | — | — | US | disclosed |
| EP-0840781-A4 | METHODS AND DEVICES FOR THE REMOVAL OF PSORALENS FROM BLOOD PRODUCTS | CERUS CORP (US) | 2001-03-21 | — | — | EP | disclosed |
| US-5919935-A | Psoralen sensitizers for viral inactivation | THE OHIO STATE RESEARCH FOUNDATION (US) | 1999-07-06 | — | — | US | disclosed |
| WO-1998022468-A1 | PSORALEN SENSITIZERS FOR VIRAL INACTIVATION | OHIO STATE RESEARCH FOUNDATION (US) | 1998-05-28 | — | — | WO | disclosed |
| EP-0840781-A1 | METHODS AND DEVICES FOR THE REMOVAL OF PSORALENS FROM BLOOD PRODUCTS | Cerus Corporation (US) | 1998-05-13 | — | — | EP | disclosed |
| WO-1996040857-A1 | METHODS AND DEVICES FOR THE REMOVAL OF PSORALENS FROM BLOOD PRODUCTS | CERUS CORPORATION (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115585-A1 | Method and devices for the removal of psoralens from blood products | SERPINB10, RAD50, F2 | KCNA2 4811/4885CYP1A1 2107/4885KDM4E 3546/4885 |
| US-20020192632-A1 | Method and devices for the removal of psoralens from blood products | PLG, SERPINB10, RAD50 | KCNA2 4775/4885CYP1A1 1432/4885KDM4E 3483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.